Curis priced a USD 5.6 million offering and Curis stock fell 10.61 percent

Published on 10/08/2026 at 17:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Curis stock costs EUR 0.59 on October 8, 2026 after EUR 0.66, down 10.61 percent. Adjusted EPS was USD -4.02 versus USD -5.70 expected.

Key points in brief

Curis priced a USD 5.6 million public offering on August 13, 2026.
Second-quarter adjusted earnings per share improved to USD -4.02 from USD -25.00 in the first quarter.
The stock was EUR 0.59 at Lang & Schwarz on October 8, 2026, down 10.61 percent versus the prior close.
Curis is developing emavusertib for cancer indications and has a next earnings date of November 5, 2026.

CRIS, US2312694084, Illustration mit AI erstellt.

Curis (ISIN US2312694084) had priced a USD 5.6 million public offering on August 13, 2026, according to Curis. Curis stock was EUR 0.59 at Lang & Schwarz on October 8, 2026, down 10.61 percent versus the prior close.

Three financing and trial milestones

On May 12, 2026, Curis reported a first-quarter adjusted loss per share of USD -25.00, according to Earnings Today.

On July 30, 2026, Curis said it had dosed the first five patients in its TakeAim CLL study, per the Curis investor release. The company had then priced the USD 5.6 million public offering on August 13, 2026, according to MarketScreener.

What did the second quarter show?

For the quarter ended June 30, 2026, Curis reported adjusted earnings per share of USD -4.02, compared with USD -5.70 expected, a 29.50 percent improvement against consensus, according to Earnings Today. Net income was a loss of USD 8.58 million, while revenue was USD 0 for the same quarter.

The comparison with the first quarter is stark: adjusted earnings per share improved from USD -25.00 to USD -4.02, but the company still reported a loss and no quarterly revenue. Curis is a clinical-stage biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor, with cancer studies providing the main operating focus.

Next reporting date is November 5

Earnings Today lists November 5, 2026, as Curis' next scheduled report date. Curis trades on the Nasdaq under ticker CRIS, and the upcoming report will provide the next dated test of the company's financing position and clinical progress.

EUR 0.59 after hours

The Lang & Schwarz quote stood at EUR 0.59 after hours on October 8, 2026, versus a prior close of EUR 0.66, a decline of 10.61 percent. Curis' primary listing is Nasdaq, where its quotation currency is USD.

The further course of trading is shown by the continuously updated real-time quote of Curis stock.